Výsledky vyhledávání

Combinatorial drug screening identifies synergistic interactions of Bcl-2 inhibitor Navitoclax with MELK inhibitor OTSSP167 and HDAC inhibitor Panobinostat for the treatment of aggressive meningiomas

Autor: Cao, J, Jungwirth, G, Warta, R, Unterberg, AW, Herold-Mende, C

Publikováno v: 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie; 20220529-20220601; Köln; DOCV308 /20220525/

Objective: Combinatorial targeted therapy has been suggested as a powerful approach to overcome drug resistance and also might lead to a dose reduction of the single drugs. Based on a previous drug screening in meningioma cell lines, we identified OT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f1383448b8b5dc16d0227f6db2fd7f

Zobrazit plný text záznamu

Identification of synergistic drug combinations for therapy of IDH-mutated glioma

Autor: Stammler, F, Warta, R, Herold-Mende, C, Unterberg, AW

Objective: Isocitrate Dehydrogenase-mutated (IDHmut) and wildtype (IDHwt) gliomas are regarded as separate tumor entities with the need for accordingly adjusted therapies. IDHmut tumors have a better prognosis than the wildtype. Nevertheless they are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1e7297afb53e53fb34f92d248ffb9fd

Zobrazit plný text záznamu

Towards precision medicine – automated drug screening platform utilising Tumour-Organoids to identify patient-specific drug-responses

Autor: Jungwirth, G, Paul, A, Cao, J, Warta, R, Abdollahi, A, Unterberg, AW, Herold-Mende, C

Objective: Tumor-organoids (TO) are mini-tumors generated from tumor tissue preserving its genotype and phenotype by maintaining the cellular heterogeneity and important components of the tumor microenvironment. We recently developed a protocol to re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c05926d4db1daaf02009cc8770e7839e

Zobrazit plný text záznamu

Large-scale drug screening of FDA-approved antineoplastic drugs identifies Ixabepilone for the treatment of aggressive meningiomas

Autor: Jungwirth, G, Yu, T, Liu, F, Warta, R, Unterberg, AW, Herold-Mende, C

Publikováno v: 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie; 20210606-20210609; sine loco [digital]; DOCV123 /20210604/

Objective: The management of aggressive meningiomas remains challenging due to limited treatment options beside surgical removal and radiotherapy. High recurrence rates and lack of effective chemotherapies may be reasons for unfavorable prognosis of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53d5d3adb2f0853bf9d28927b1a3d198

Zobrazit plný text záznamu

Tumour-associated macrophages are independent prognostic markers in meningiomas

Autor: Liu, F, Jungwirth, G, Warta, R, Herold-Mende, C, Unterberg, AW

Objective: Tumour-associated macrophages (TAMs) play an emerging role in tumour progression by creating an immunosuppressive tumour microenvironment. Therefore, we investigated TAM numbers and their activation (M1/2) in primary (p‑) and recurrent (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1aae471c29f96ea3e789674a302b98f

Zobrazit plný text záznamu

Cancer-derived organoids as novel drug screening platform identifies panobinostat and OTSSP167 as highly potent drugs in meningioma

Autor: Jungwirth, G, Cao, J, Yu, T, Warta, R, Unterberg, AW, Herold-Mende, C

Objective: Cancer-derived organoids (CDOs) are novel, complex three-dimensional ex vivo tissue cultures that accurately reflect genotype and phenotype of the original tumor with preserved cellular heterogeneity and structural architecture. They offer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::263b622f4ebb381d69831818b7237908

Zobrazit plný text záznamu

High-throughput drug screening of FDA-approved antineoplastic drugs for the treatment of aggressive meningiomas

Autor: Jungwirth, G, Yu, T, Liu, F, Warta, R, Herold-Mende, C, Unterberg, AW

Publikováno v: 71. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 9. Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie; 20200621-20200624; sine loco [digital]; DOCV034 /20200626/

Objective: Treatment of aggressive meningiomas is still challenging for a couple of reasons, including high rate of recurrence of higher-grade meningiomas, impossible total resection and a lack of effective chemotherapies. To address this urgent need

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72328c26a2935b062634200cfa52282f

Zobrazit plný text záznamu

Large-scale drug screen in patient-derived IDHmut glioma stem cells identifies several FDA-approved antineoplastic agents

Autor: Dao Trong, P, Jungwirth, G, Yu, T, Pusch, S, Herold-Mende, C, Warta, R, Unterberg, AW

Objective: The discovery of the Isocitrate Dehydrogenase (IDH) mutation in glioma has led to a paradigm shift on how we see glioma biology. While it is clear that IDH mutated (IDHmut) and wildtype (IDHwt) tumors have to be viewed as separate entities

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7b151dd7917f5a3b3d6b303ec1c44ac

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Non-NF2 intraventricular meningiomas lack the common genetic alterations of TRAF7, AKT1, SMO, KLF4, PIK3CA and TERT

Autor: Jungwirth, G, Warta, R, von Deimling, A, Sahm, F, Unterberg, A, Herold-Mende, C, Jungk, C

Publikováno v: 70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie; 20190512-20190515; Würzburg; DOCP091 /20190508/

Objective: Intraventricular meningiomas (IVMs) are rare tumors which only account for 0.5–3% of all meningiomas (MGMs) and up to 14% of all intraventricular tumors. Although there is increasing knowledge about the clinical and molecular features of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dcb29691791eddc932bf41a006c1183

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání